This pilot phase 0 trial studies how well positron emission tomography (PET)/computed tomopgraphy (CT) imaging with iodine I 124-labeled heat shock protein (HSP)90 inhibitor PUH71 (124I-PUH71) works in imaging patients with solid tumor, myeloproliferative neoplasm, plasma cell myeloma, or lymphoma. PET/CT imaging using 124I-PUH71 may be a better way to detect cancer and may help doctors plan treatment of cancer.
Additional locations may be listed on ClinicalTrials.gov for NCT01269593.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVE:
I. To study the pharmacokinetics, metabolism, and biodistribution of iodine I 124-labeled HSP90 inhibitor PUH71 (124I-PUH71) in patients with active myeloproliferative neoplasms, solid malignancy and/or lymphoma.
OUTLINE:
Patients receive iodine I 124-labeled HSP90 inhibitor PUH71 intravenously (IV) and undergo PET/CT scans over 30-45 minutes at 3-4, 20-24, and 40-48 hours after iodine I 124-labeled HSP90 inhibitor PUH71 injection. Patients may also undergo PET/CT scans immediately and 160-200 hours after iodine I 124-labeled HSP90 inhibitor PUH71 injection.
After completion of study, patients are followed up at 6-12 months.
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorMark Dunphy
